1	Delmed	_	NNP	_	_	2	NAME	_	_
2	Inc.	_	NNP	_	_	6	NMOD	_	_
3	's	_	POS	_	_	2	SUFFIX	_	_
4	top	_	JJ	_	_	6	NMOD	_	_
5	two	_	CD	_	_	6	NMOD	_	_
6	officers	_	NNS	_	_	7	SBJ	_	_
7	resigned	_	VBD	_	_	0	ROOT	_	_
8	and	_	CC	_	_	7	COORD	_	_
9	were	_	VBD	_	_	8	CONJ	_	_
10	succeeded	_	VBN	_	_	9	VC	_	_
11	by	_	IN	_	_	10	LGS	_	_
12	executives	_	NNS	_	_	11	PMOD	_	_
13	of	_	IN	_	_	12	NMOD	_	_
14	Fresenius	_	NNP	_	_	15	NAME	_	_
15	USA	_	NNP	_	_	13	PMOD	_	_
16	Inc.	_	NNP	_	_	15	POSTHON	_	_
17	and	_	CC	_	_	15	COORD	_	_
18	its	_	PRP$	_	_	19	NMOD	_	_
19	parent	_	NN	_	_	17	CONJ	_	_
20	,	_	,	_	_	19	P	_	_
21	Fresenius	_	NNP	_	_	22	NAME	_	_
22	AG	_	NNP	_	_	19	COORD	_	_
23	,	_	,	_	_	22	P	_	_
24	a	_	DT	_	_	27	NMOD	_	_
25	major	_	JJ	_	_	27	NMOD	_	_
26	Delmed	_	NNP	_	_	27	NMOD	_	_
27	holder	_	NN	_	_	22	COORD	_	_
28	that	_	WDT	_	_	29	SBJ	_	_
29	has	_	VBZ	_	_	27	NMOD	_	_
30	been	_	VBN	_	_	29	VC	_	_
31	negotiating	_	VBG	_	_	30	VC	_	_
32	to	_	TO	_	_	31	OPRD	_	_
33	acquire	_	VB	_	_	32	IM	_	_
34	a	_	DT	_	_	36	NMOD	_	_
35	controlling	_	JJ	_	_	36	NMOD	_	_
36	stake	_	NN	_	_	33	OBJ	_	_
37	.	_	.	_	_	7	P	_	_

1	In	_	IN	_	_	19	ADV	_	_
2	addition	_	NN	_	_	1	PMOD	_	_
3	,	_	,	_	_	19	P	_	_
4	Delmed	_	NNP	_	_	19	SBJ	_	_
5	,	_	,	_	_	4	P	_	_
6	which	_	WDT	_	_	7	SBJ	_	_
7	makes	_	VBZ	_	_	4	NMOD	_	_
8	and	_	CC	_	_	7	COORD	_	_
9	sells	_	VBZ	_	_	8	CONJ	_	_
10	a	_	DT	_	_	12	NMOD	_	_
11	dialysis	_	NN	_	_	12	NMOD	_	_
12	solution	_	NN	_	_	7	OBJ	_	_
13	used	_	VBN	_	_	12	APPO	_	_
14	in	_	IN	_	_	13	LOC	_	_
15	treating	_	VBG	_	_	14	PMOD	_	_
16	kidney	_	NN	_	_	17	NMOD	_	_
17	diseases	_	NNS	_	_	15	OBJ	_	_
18	,	_	,	_	_	4	P	_	_
19	said	_	VBD	_	_	0	ROOT	_	_
20	negotiations	_	NNS	_	_	23	SBJ	_	_
21	about	_	IN	_	_	20	NMOD	_	_
22	pricing	_	NN	_	_	21	PMOD	_	_
23	had	_	VBD	_	_	19	OBJ	_	_
24	collapsed	_	VBN	_	_	23	VC	_	_
25	between	_	IN	_	_	20	NMOD	_	_
26	it	_	PRP	_	_	25	PMOD	_	_
27	and	_	CC	_	_	26	COORD	_	_
28	a	_	DT	_	_	30	NMOD	_	_
29	major	_	JJ	_	_	30	NMOD	_	_
30	distributor	_	NN	_	_	27	CONJ	_	_
31	,	_	,	_	_	30	P	_	_
32	National	_	NNP	_	_	34	NAME	_	_
33	Medical	_	NNP	_	_	34	NAME	_	_
34	Care	_	NNP	_	_	30	APPO	_	_
35	Inc	_	NNP	_	_	34	POSTHON	_	_
36	.	_	.	_	_	19	P	_	_

1	Delmed	_	NNP	_	_	2	SBJ	_	_
2	said	_	VBD	_	_	0	ROOT	_	_
3	Robert	_	NNP	_	_	5	NAME	_	_
4	S.	_	NNP	_	_	5	NAME	_	_
5	Ehrlich	_	NNP	_	_	6	SBJ	_	_
6	resigned	_	VBD	_	_	2	OBJ	_	_
7	as	_	IN	_	_	6	ADV	_	_
8	chairman	_	NN	_	_	7	PMOD	_	_
9	,	_	,	_	_	8	P	_	_
10	president	_	NN	_	_	8	COORD	_	_
11	and	_	CC	_	_	10	COORD	_	_
12	chief	_	JJ	_	_	13	NMOD	_	_
13	executive	_	NN	_	_	11	CONJ	_	_
14	.	_	.	_	_	2	P	_	_

1	Mr.	_	NNP	_	_	2	TITLE	_	_
2	Ehrlich	_	NNP	_	_	3	SBJ	_	_
3	will	_	MD	_	_	0	ROOT	_	_
4	continue	_	VB	_	_	3	VC	_	_
5	as	_	IN	_	_	4	ADV	_	_
6	a	_	DT	_	_	7	NMOD	_	_
7	director	_	NN	_	_	5	PMOD	_	_
8	and	_	CC	_	_	7	COORD	_	_
9	a	_	DT	_	_	10	NMOD	_	_
10	consultant	_	NN	_	_	8	CONJ	_	_
11	.	_	.	_	_	3	P	_	_

1	Leslie	_	NNP	_	_	3	NAME	_	_
2	I.	_	NN	_	_	3	NMOD	_	_
3	Shapiro	_	NNP	_	_	14	SBJ	_	_
4	,	_	,	_	_	3	P	_	_
5	chief	_	JJ	_	_	7	NMOD	_	_
6	operating	_	VBG	_	_	7	NMOD	_	_
7	officer	_	NN	_	_	3	APPO	_	_
8	and	_	CC	_	_	7	COORD	_	_
9	chief	_	JJ	_	_	11	NMOD	_	_
10	financial	_	JJ	_	_	11	NMOD	_	_
11	officer	_	NN	_	_	8	CONJ	_	_
12	,	_	,	_	_	3	P	_	_
13	also	_	RB	_	_	14	ADV	_	_
14	resigned	_	VBN	_	_	18	OBJ	_	_
15	,	_	,	_	_	18	P	_	_
16	the	_	DT	_	_	17	NMOD	_	_
17	company	_	NN	_	_	18	SBJ	_	_
18	said	_	VBD	_	_	0	ROOT	_	_
19	.	_	.	_	_	18	P	_	_

1	Mr.	_	NNP	_	_	2	TITLE	_	_
2	Ehrlich	_	NNP	_	_	3	SBJ	_	_
3	was	_	VBD	_	_	0	ROOT	_	_
4	succeeded	_	VBN	_	_	3	VC	_	_
5	as	_	IN	_	_	4	ADV	_	_
6	chairman	_	NN	_	_	5	PMOD	_	_
7	by	_	IN	_	_	4	LGS	_	_
8	Gerd	_	NNP	_	_	9	NAME	_	_
9	Krick	_	NNP	_	_	7	PMOD	_	_
10	,	_	,	_	_	9	P	_	_
11	a	_	DT	_	_	12	NMOD	_	_
12	director	_	NN	_	_	9	APPO	_	_
13	of	_	IN	_	_	12	NMOD	_	_
14	Fresenius	_	NNP	_	_	13	PMOD	_	_
15	,	_	,	_	_	14	P	_	_
16	a	_	DT	_	_	20	NMOD	_	_
17	West	_	JJ	_	_	18	AMOD	_	_
18	German	_	JJ	_	_	20	NMOD	_	_
19	pharmaceutical	_	JJ	_	_	20	NMOD	_	_
20	concern	_	NN	_	_	14	APPO	_	_
21	.	_	.	_	_	3	P	_	_

1	Ben	_	NNP	_	_	2	NAME	_	_
2	Lipps	_	NNP	_	_	9	SBJ	_	_
3	,	_	,	_	_	2	P	_	_
4	president	_	NN	_	_	2	APPO	_	_
5	of	_	IN	_	_	4	NMOD	_	_
6	Fresenius	_	NNP	_	_	7	NAME	_	_
7	USA	_	NNP	_	_	5	PMOD	_	_
8	,	_	,	_	_	2	P	_	_
9	was	_	VBD	_	_	0	ROOT	_	_
10	named	_	VBN	_	_	9	VC	_	_
11	president	_	NN	_	_	10	OPRD	_	_
12	,	_	,	_	_	11	P	_	_
13	chief	_	JJ	_	_	14	NMOD	_	_
14	executive	_	NN	_	_	11	COORD	_	_
15	and	_	CC	_	_	14	COORD	_	_
16	chief	_	JJ	_	_	18	NMOD	_	_
17	operating	_	VBG	_	_	18	NMOD	_	_
18	officer	_	NN	_	_	15	CONJ	_	_
19	.	_	.	_	_	9	P	_	_

1	None	_	NN	_	_	5	SBJ	_	_
2	of	_	IN	_	_	1	NMOD	_	_
3	the	_	DT	_	_	4	NMOD	_	_
4	officials	_	NNS	_	_	2	PMOD	_	_
5	was	_	VBD	_	_	0	ROOT	_	_
6	available	_	JJ	_	_	5	PRD	_	_
7	for	_	IN	_	_	6	AMOD	_	_
8	comment	_	NN	_	_	7	PMOD	_	_
9	.	_	.	_	_	5	P	_	_

1	In	_	IN	_	_	10	LOC	_	_
2	trading	_	NN	_	_	1	PMOD	_	_
3	on	_	IN	_	_	2	LOC	_	_
4	the	_	DT	_	_	7	NMOD	_	_
5	American	_	NNP	_	_	7	NAME	_	_
6	Stock	_	NNP	_	_	7	NAME	_	_
7	Exchange	_	NNP	_	_	3	PMOD	_	_
8	,	_	,	_	_	10	P	_	_
9	Delmed	_	NNP	_	_	10	SBJ	_	_
10	closed	_	VBD	_	_	0	ROOT	_	_
11	at	_	IN	_	_	10	ADV	_	_
12	50	_	CD	_	_	13	NMOD	_	_
13	cents	_	NNS	_	_	11	PMOD	_	_
14	,	_	,	_	_	10	P	_	_
15	down	_	RB	_	_	10	ADV	_	_
16	6.25	_	CD	_	_	17	NMOD	_	_
17	cents	_	NNS	_	_	15	AMOD	_	_
18	.	_	.	_	_	10	P	_	_

1	Fresenius	_	NNP	_	_	2	SBJ	_	_
2	owns	_	VBZ	_	_	0	ROOT	_	_
3	about	_	IN	_	_	4	DEP	_	_
4	42	_	CD	_	_	5	NMOD	_	_
5	%	_	NN	_	_	2	OBJ	_	_
6	of	_	IN	_	_	5	NMOD	_	_
7	Delmed	_	NNP	_	_	12	NMOD	_	_
8	's	_	POS	_	_	7	SUFFIX	_	_
9	fully	_	RB	_	_	10	AMOD	_	_
10	diluted	_	JJ	_	_	12	NMOD	_	_
11	common	_	JJ	_	_	12	NMOD	_	_
12	stock	_	NN	_	_	6	PMOD	_	_
13	.	_	.	_	_	2	P	_	_

1	The	_	DT	_	_	3	NMOD	_	_
2	two	_	CD	_	_	3	NMOD	_	_
3	companies	_	NNS	_	_	4	SBJ	_	_
4	have	_	VBP	_	_	0	ROOT	_	_
5	been	_	VBN	_	_	4	VC	_	_
6	discussing	_	VBG	_	_	5	VC	_	_
7	a	_	DT	_	_	8	NMOD	_	_
8	transaction	_	NN	_	_	6	OBJ	_	_
9	under	_	IN	_	_	13	ADV	_	_
10	which	_	WDT	_	_	9	PMOD	_	_
11	Fresenius	_	NNP	_	_	12	SBJ	_	_
12	would	_	MD	_	_	8	NMOD	_	_
13	buy	_	VB	_	_	12	VC	_	_
14	Delmed	_	NNP	_	_	15	NMOD	_	_
15	stock	_	NN	_	_	13	OBJ	_	_
16	for	_	IN	_	_	13	ADV	_	_
17	cash	_	NN	_	_	16	PMOD	_	_
18	to	_	TO	_	_	13	PRP	_	_
19	bring	_	VB	_	_	18	IM	_	_
20	its	_	PRP$	_	_	22	NMOD	_	_
21	beneficial	_	JJ	_	_	22	NMOD	_	_
22	ownership	_	NN	_	_	19	OBJ	_	_
23	to	_	TO	_	_	19	ADV	_	_
24	between	_	IN	_	_	26	DEP	_	_
25	70	_	CD	_	_	26	COORD	_	_
26	%	_	NN	_	_	23	PMOD	_	_
27	and	_	CC	_	_	26	COORD	_	_
28	80	_	CD	_	_	27	CONJ	_	_
29	%	_	NN	_	_	28	COORD	_	_
30	of	_	IN	_	_	26	NMOD	_	_
31	Delmed	_	NNP	_	_	36	NMOD	_	_
32	's	_	POS	_	_	31	SUFFIX	_	_
33	fully	_	RB	_	_	34	AMOD	_	_
34	diluted	_	JJ	_	_	36	NMOD	_	_
35	common	_	JJ	_	_	36	NMOD	_	_
36	stock	_	NN	_	_	30	PMOD	_	_
37	.	_	.	_	_	4	P	_	_

1	The	_	DT	_	_	2	NMOD	_	_
2	transaction	_	NN	_	_	4	SBJ	_	_
3	also	_	RB	_	_	4	ADV	_	_
4	would	_	MD	_	_	0	ROOT	_	_
5	combine	_	VB	_	_	4	VC	_	_
6	Fresenius	_	NNP	_	_	7	NAME	_	_
7	USA	_	NNP	_	_	5	OBJ	_	_
8	and	_	CC	_	_	7	COORD	_	_
9	Delmed	_	NNP	_	_	8	CONJ	_	_
10	.	_	.	_	_	4	P	_	_

1	Under	_	IN	_	_	6	ADV	_	_
2	the	_	DT	_	_	3	NMOD	_	_
3	proposal	_	NN	_	_	1	PMOD	_	_
4	,	_	,	_	_	6	P	_	_
5	Delmed	_	NNP	_	_	6	SBJ	_	_
6	would	_	MD	_	_	0	ROOT	_	_
7	issue	_	VB	_	_	6	VC	_	_
8	about	_	IN	_	_	10	DEP	_	_
9	123.5	_	CD	_	_	10	DEP	_	_
10	million	_	CD	_	_	14	NMOD	_	_
11	additional	_	JJ	_	_	14	NMOD	_	_
12	Delmed	_	NNP	_	_	14	NMOD	_	_
13	common	_	JJ	_	_	14	NMOD	_	_
14	shares	_	NNS	_	_	7	OBJ	_	_
15	to	_	TO	_	_	7	DTV	_	_
16	Fresenius	_	NNP	_	_	15	PMOD	_	_
17	at	_	IN	_	_	7	ADV	_	_
18	an	_	DT	_	_	20	NMOD	_	_
19	average	_	JJ	_	_	20	NMOD	_	_
20	price	_	NN	_	_	17	PMOD	_	_
21	of	_	IN	_	_	20	NMOD	_	_
22	about	_	IN	_	_	23	DEP	_	_
23	65	_	CD	_	_	24	NMOD	_	_
24	cents	_	NNS	_	_	21	PMOD	_	_
25	a	_	DT	_	_	26	NMOD	_	_
26	share	_	NN	_	_	24	ADV	_	_
27	,	_	,	_	_	24	P	_	_
28	though	_	IN	_	_	24	ADV	_	_
29	under	_	IN	_	_	35	ADV	_	_
30	no	_	DT	_	_	31	NMOD	_	_
31	circumstances	_	NNS	_	_	29	PMOD	_	_
32	more	_	JJR	_	_	34	DEP	_	_
33	than	_	IN	_	_	34	DEP	_	_
34	75	_	CD	_	_	35	NMOD	_	_
35	cents	_	NNS	_	_	28	SUB	_	_
36	a	_	DT	_	_	37	NMOD	_	_
37	share	_	NN	_	_	35	ADV	_	_
38	.	_	.	_	_	6	P	_	_

1	Yesterday	_	NN	_	_	4	TMP	_	_
2	,	_	,	_	_	4	P	_	_
3	Delmed	_	NNP	_	_	4	SBJ	_	_
4	said	_	VBD	_	_	0	ROOT	_	_
5	it	_	PRP	_	_	7	SBJ	_	_
6	``	_	``	_	_	7	P	_	_
7	continues	_	VBZ	_	_	4	OBJ	_	_
8	to	_	TO	_	_	7	OPRD	_	_
9	explore	_	VB	_	_	8	IM	_	_
10	the	_	DT	_	_	11	NMOD	_	_
11	possibility	_	NN	_	_	9	OBJ	_	_
12	of	_	IN	_	_	11	NMOD	_	_
13	a	_	DT	_	_	14	NMOD	_	_
14	combination	_	NN	_	_	12	PMOD	_	_
15	with	_	IN	_	_	14	NMOD	_	_
16	Fresenius	_	NNP	_	_	17	NAME	_	_
17	USA	_	NNP	_	_	15	PMOD	_	_
18	.	_	.	_	_	4	P	_	_
19	''	_	''	_	_	4	P	_	_

1	It	_	PRP	_	_	2	SBJ	_	_
2	added	_	VBD	_	_	0	ROOT	_	_
3	that	_	IN	_	_	2	OBJ	_	_
4	it	_	PRP	_	_	5	SBJ	_	_
5	is	_	VBZ	_	_	3	SUB	_	_
6	apparent	_	JJ	_	_	5	PRD	_	_
7	that	_	IN	_	_	5	EXTR	_	_
8	any	_	DT	_	_	9	NMOD	_	_
9	terms	_	NNS	_	_	14	SBJ	_	_
10	of	_	IN	_	_	9	NMOD	_	_
11	a	_	DT	_	_	12	NMOD	_	_
12	combination	_	NN	_	_	10	PMOD	_	_
13	``	_	``	_	_	14	P	_	_
14	would	_	MD	_	_	7	SUB	_	_
15	be	_	VB	_	_	14	VC	_	_
16	substantially	_	RB	_	_	18	AMOD	_	_
17	less	_	RBR	_	_	18	AMOD	_	_
18	favorable	_	JJ	_	_	15	PRD	_	_
19	than	_	IN	_	_	18	AMOD	_	_
20	those	_	DT	_	_	19	PMOD	_	_
21	previously	_	RB	_	_	22	TMP	_	_
22	announced	_	VBN	_	_	20	APPO	_	_
23	.	_	.	_	_	2	P	_	_
24	''	_	''	_	_	2	P	_	_

1	While	_	IN	_	_	15	ADV	_	_
2	the	_	DT	_	_	3	NMOD	_	_
3	discussions	_	NNS	_	_	10	SBJ	_	_
4	between	_	IN	_	_	3	NMOD	_	_
5	Delmed	_	NNP	_	_	4	PMOD	_	_
6	and	_	CC	_	_	5	COORD	_	_
7	National	_	NNP	_	_	9	NAME	_	_
8	Medical	_	NNP	_	_	9	NAME	_	_
9	Care	_	NNP	_	_	6	CONJ	_	_
10	have	_	VBP	_	_	1	SUB	_	_
11	been	_	VBN	_	_	10	VC	_	_
12	discontinued	_	VBN	_	_	11	VC	_	_
13	,	_	,	_	_	15	P	_	_
14	Delmed	_	NNP	_	_	15	SBJ	_	_
15	will	_	MD	_	_	34	OBJ	_	_
16	continue	_	VB	_	_	15	VC	_	_
17	to	_	TO	_	_	16	OPRD	_	_
18	supply	_	VB	_	_	17	IM	_	_
19	dialysis	_	NN	_	_	20	NMOD	_	_
20	products	_	NNS	_	_	18	OBJ	_	_
21	through	_	IN	_	_	18	MNR	_	_
22	National	_	NNP	_	_	23	NAME	_	_
23	Medical	_	NNP	_	_	21	PMOD	_	_
24	after	_	IN	_	_	16	TMP	_	_
25	their	_	PRP$	_	_	27	NMOD	_	_
26	exclusive	_	JJ	_	_	27	NMOD	_	_
27	agreement	_	NN	_	_	28	SBJ	_	_
28	ends	_	NNS	_	_	24	SUB	_	_
29	in	_	IN	_	_	28	TMP	_	_
30	March	_	NNP	_	_	29	PMOD	_	_
31	1990	_	CD	_	_	30	NMOD	_	_
32	,	_	,	_	_	34	P	_	_
33	Delmed	_	NNP	_	_	34	SBJ	_	_
34	said	_	VBD	_	_	0	ROOT	_	_
35	.	_	.	_	_	34	P	_	_

1	In	_	IN	_	_	5	ADV	_	_
2	addition	_	NN	_	_	1	PMOD	_	_
3	,	_	,	_	_	5	P	_	_
4	Delmed	_	NNP	_	_	5	SBJ	_	_
5	is	_	VBZ	_	_	14	OBJ	_	_
6	exploring	_	VBG	_	_	5	VC	_	_
7	distribution	_	NN	_	_	8	NMOD	_	_
8	arrangements	_	NNS	_	_	6	OBJ	_	_
9	with	_	IN	_	_	6	ADV	_	_
10	Fresenius	_	NNP	_	_	11	NAME	_	_
11	USA	_	NNP	_	_	9	PMOD	_	_
12	,	_	,	_	_	14	P	_	_
13	Delmed	_	NNP	_	_	14	SBJ	_	_
14	said	_	VBD	_	_	0	ROOT	_	_
15	.	_	.	_	_	14	P	_	_

